Meetings barred from five-star hotels

Share this article:
International meeting planners may be chafing this month from a new rule barring pharmaceutical companies from supporting educational events at luxury venues. But in the US, where reform has been under way for a decade, it's expected to have minimal impact.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) adopted the rule as part of a set of updates to its Code of Pharmaceutical Marketing Practice that went into effect January 1. IFPMA, whose 26 member companies include Sanofi-Aventis, Pfizer and  GlaxoSmithKline, prohibits them from giving doctors money or gifts that might influence drug choices but allows inexpensive gifts.

IFPMA Director General Dr Harvey Bale told MM&M the new code will have “only marginal effect” on educational events. “Already, US doctors are facing the fact that companies will not pay spousal travel expenses, and meetings are principally focused on scientific content relative to surroundings,” he said via e-mail from IFPMA headquarters in Geneva.

Nor does he expect countries to restrict their investment in educational events as a result.

“As far as industry is concerned, tightening of ethical promotion oversight will have zero effect on educational events,” he added.

Lew Miller, WentzMiller & Associates principal, said the new code won't have much of an impact on European events, either, since the drug industry has strong guidelines there, too. But people booking conventions in second- and third-world countries may feel its effects, as will US physicians still used to traveling to extravagant places for their med ed, he said.

The area of greatest impact, said Bale, will be in implementation of the code's gift policies, a posture of zero tolerance toward offenders and a strong deterrent: publicizing violations.
“Our goal is to prevent stupid events of the past that undermine public confidence in the industry from happening again in the future.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...